The aim of this study is to investigate the clinical value of \[18F\]aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide（18F-AlF-NOTA-octreotide ） positron emission tomography / computed tomography (PET/CT) in patients with neuroendocrine neoplasms (NENs).
18F-AlF-NOTA-octreotide is a radioligand targeting the somatostatin receptor, which is widely expressed on the cell surface of NENs. The radioligand can be used for the diagnosis and stage of the NENs. A total of 5 volunteers and 60 NEN patients will be subjected to a 18F-AlF-NOTA-octreotide PET/CT scan. The uptake of 18F-AlF-NOTA-octreotide in organs and tumor lesions will be quantified as Standardized Uptake Values (SUVmax/SUVmean).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
65
One injection of 18F-AlF-NOTA-octreotide
Following injection of 18F-AlF-NOTA-octreotide the participants will be subjected to whole body PET/CT
Department of PET Center,Xiangya Hospital,Central South University
Changsha, Hunan, China
RECRUITING18F-AlF-NOTA-octreotide PET/CT imaging of patients with Neuroendocrine Neoplasms
The radioligand 18F-AlF-NOTA-octreotide can be used to visualize neuroendocrine neoplasms
Time frame: 12 months
18F-AlF-NOTA-octreotide PET/CT prognostic factor for overall and disease specific survival
The uptake of the 18F-AlF-NOTA-octreotide in neuroendocrine neoplasm lesions (quantified as Standard Uptake Values) is associated with overall and disease specific free survival (PFS) neuroendocrine neoplasms
Time frame: 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.